David Faber
Psychiatry · Pelham, ALNPI 1639117740
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,199 and has fallen 59.3% since, to $488 in 2021.
Across 116 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$391
- Takeda Pharmaceuticals U.S.A., Inc.$280
- Neos Therapeutics, LP$139
- Alkermes, Inc.$134
- Shire North American Group Inc$128
- Ironshore Pharmaceuticals Inc.$119
- plus $763 from 15 others
What the payments were for
- Food & beverage$1,954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $280 |
| Neos Therapeutics, LP | 7 | $139 |
| Alkermes, Inc. | 3 | $134 |
| Shire North American Group Inc | 10 | $128 |
| Ironshore Pharmaceuticals Inc. | 6 | $119 |
| Johnson & Johnson | 8 | $113 |
| Teva Pharmaceuticals USA, Inc. | 6 | $85 |
| Indivior Inc. | 4 | $83 |
| Tris Pharma Inc | 5 | $81 |
| Orexo US, Inc. | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $61 |
| Adlon Therapeutics L.p. | 2 | $46 |
| Lundbeck LLC | 2 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $29 |
| Vertical Pharmaceuticals, LLC | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Rhodes Pharmaceuticals L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$106
How this compares
$1,954 in reported general payments places this provider in the 65th percentile of 400 psychiatry providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 38 | $1,147 |
| Alprazolam | 159 | $774 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $610 |
| Clonazepam | 118 | $501 |
| Lorazepam | 49 | $314 |
| Zolpidem Tartrate | 29 | $261 |
| Gabapentin | 23 | $248 |
| Diazepam | 46 | $188 |
| Risperidone | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pelham
- Annie AndrewsPelham$5K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.